Phase 2 Trial of PD-1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma.

ABSTRACT:

Background

Systemic therapeutic options for meningiomas remain limited. Emerging evidence indicates meningiomas harbor an immunosuppressive microenvironment and programmed cell death ligand 1 (PD-L1) expression is significantly upregulated in both tumor cells and tumor-infiltrating immune cells. Here we conducted a single-arm, single-center, open-label, phase 2 clinical trial (NCT04728568) evaluating the programmed cell death receptor-1 (PD-1) inhibitor sintilimab in patients with recurrent/progressive meningiomas following standard surgery and/or radiotherapy.

Methods

Forty patients (9 grade 1, 18 grade 2, and 13 grade 3) received intravenous sintilimab (200 mg every 3 weeks). According to Response Assessment in Neuro-Oncology for meningioma (RANO-meningioma) criteria, the

SUBMITTER: Wang Y 

PROVIDER: S-EPMC12683679 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature